Cessation Therapeutics, Inc.
San Jose, CA · Founded 2022 · CIK 0001926434 · Biotech · Private
High-affinity anti-nicotine monoclonal antibodies developed through novel vaccine design for smoking cessation
cessationtherapeutics.com →- Grants
- $422K
- 2 awards
- Sector median: 1
- Raised
- $6.8M
- 2 Form D · Apr 2024
- 30 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2018201920202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Development of Therapeutic Anti-Nicotine Monoclonal Antibodies through Trivalent Vaccine Design | $211,174 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of Therapeutic Anti-Nicotine Monoclonal Antibodies through Trivalent Vaccine Design | $211,174 | |
| Private capital raised | Form D · SEC | $5,755,000 | |
| Private capital raised | Form D · SEC | $1,000,000 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1173 | MediSix Therapeutics, Inc. | — | $35M |
| 1174 | ISOThrive Inc. | — | $17M |
| 1175 | Unleash Immuno Oncolytics, Inc. | — | $3.0M |
| 1176 | Cessation Therapeutics, Inc. | — | $6.8M |
| 1177 | Dnalite Therapeutics, Inc. | — | $5.6M |
| 1178 | Xenon Pharmaceuticals | — | — |
| 1179 | Pagari Life Science Corp. | — | $678K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Andrew BarrettExecutive Officer
- Daniel FineDirector
- David GenecovDirector
- John HarkeyDirector · Executive Officer
- Mark PearsonDirector · Executive Officer
- Eric RasmussenExecutive Officer
- Jay ShepardDirector
- Sharon TetlowDirector
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.